Lilly warned over Alimta patient booklet

Share this article:
The FDA slapped Eli Lilly with a warning letter over a patient brochure for its oncology treatment Alimta, saying the mailer glossed over the drug's indications and failed to mention its risks.

The Division of Drug Marketing, Advertising and Communications (DDMAC) letter has called the brochure misleading “because it fails to present either approved indication for Alimta.” Namely, for non-small cell lung cancer and, when used in combination with cisplatin, for mesothelioma.

In addition, DDMAC noted, the brochure provided information on types of cancers for which the drug is not indicated, “potentially creating the impression that Alimta is approved to treat a wide range of cancers”—a point the agency called “particularly concerning” because there exist approved treatments for some of the cancers covered.

DDMAC also took issue with the brochure's omission of risk information for pregnant patients, and requested that the company immediately pull the booklet.

Share this article:
close

Next Article in News

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.